Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Coherus BioSciences secures $75mm credit facility

Executive Summary

Coherus BioSciences Inc. entered into a $75mm senior secured credit facility with Healthcare Royalty Partners. The facility matures on January 7, 2025 and bears interest at a rate of 3-month LIBOR plus 7% per year (also subject to a 4% final payment premium on the entire principal amount funded). Funds will be used to accelerate and enhance the manufacturing and sale of FDA-approved biosimilar UDENYCA (pegfilgrastim-cbqv), a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt

Related Companies